阳普医疗：预计2025年归母净利润为1200万元-1750万元，同比扭亏为盈

Core Viewpoint - The company expects a significant improvement in net profit for 2025, projecting a range of 12 million to 17.5 million yuan, compared to a loss of 118 million yuan in the same period last year [1] Revenue Performance - The company's operating revenue is anticipated to decline by 15% to 20% year-on-year [1] - The vacuum blood collection system products are primarily affected by a decrease in sales, leading to a downward trend in revenue [1] - Revenue from reagents, software products, and services is also expected to see a year-on-year decline [1] Cost Management - The company has implemented systematic cost optimization measures and refined management practices, effectively reducing manufacturing costs [1] - Despite a downward trend in product prices, the company has successfully achieved a slight increase in gross margin year-on-year [1] - The total expenses and expense ratio have decreased year-on-year due to reasonable control of expenditures and continuous optimization of the expense structure [1]